Related references
Note: Only part of the references are listed.Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy
Xiaojie Zhu et al.
SCIENTIFIC REPORTS (2015)
The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance
Huihui Chong et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Probing the paramyxovirus fusion (F) protein-refolding event from pre- to postfusion by oxidative footprinting
Taylor A. Poor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
Lu Lu et al.
NATURE COMMUNICATIONS (2014)
An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides
Pei Tong et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain
Lu Lu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2012)
The M-T Hook Structure Is Critical for Design of HIV-1 Fusion Inhibitors
Huihui Chong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Mutations of Gln64 in the HIV-1 gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the gp41 Pocket
Xiaowen Yu et al.
JOURNAL OF VIROLOGY (2012)
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Paul D. Adams et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)
SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide
Takeshi Naito et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency
Paolo Ingallinella et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Rationally Designed Anti-HIV Peptides Containing Multifunctional Domains as Molecule Probes for Studying the Mechanisms of Action of the First and Second Generation HIV Fusion Inhibitors
Zhi Qi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor
Yuxian He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Albumin-conjugated C34 Peptide HIV-1 Fusion Inhibitor EQUIPOTENT TO C34 AND T-20 IN VITRO WITH SUSTAINED ACTIVITY IN SCID-HU THY/LIV MICE
Cheryl A. Stoddart et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: Implications for designing novel anti-HIV fusion inhibitors
Yuxian He et al.
JOURNAL OF VIROLOGY (2008)
Phaser crystallographic software
Airlie J. McCoy et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)
Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis
Jing Lu et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro
M Mink et al.
JOURNAL OF VIROLOGY (2005)
Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors
SW Liu et al.
LANCET (2004)
Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates
PR Sista et al.
AIDS (2004)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
A Lazzarin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
XP Wei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Share Paper
